Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SSGJ-705
i
Other names:
SSGJ705, SSGJ-705, 705, SSGJ 705
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
3SBio
Drug class:
PD1 inhibitor, HER2 inhibitor
Related drugs:
‹
pembrolizumab (727)
nivolumab (607)
sintilimab (115)
toripalimab-tpzi (88)
camrelizumab (85)
tislelizumab-jsgr (84)
dostarlimab-gxly (43)
cemiplimab-rwlc (29)
PDR001 (22)
zimberelimab (20)
ABBV-181 (13)
pucotenlimab (12)
cadonilimab (10)
AGEN2034 (9)
penpulimab (7)
serplulimab (7)
retifanlimab-dlwr (6)
PF-06801591 (6)
JNJ-63723283 (5)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
geptanolimab (3)
iparomlimab/tuvonralimab (3)
ivonescimab (3)
MEDI0680 (2)
QL1604 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
AZD2936 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
(0)
AI-061 (0)
AMP-224 (0)
ASKG915 (0)
AUNP-12 (0)
AWT020 (0)
(0)
BAT1306 (0)
BAT1308 (0)
BGB-108 (0)
BZD1901 (0)
BiCKI IL-7 (0)
CB213 (0)
CD200AR-L (0)
CDX-585 (0)
CMAB 819 (nivolumab biosimilar) (0)
EBV-specific anti-PD1 TCR-T cells (0)
EMB-02 (0)
enlonstobart (0)
prolgolimab (0)
GNR-051 (0)
HX-009 (0)
IAP0971 (0)
INCA32459 (0)
INCA33890 (0)
JS201 (0)
KJ-101 (0)
LB1410 (0)
MASCT-I (0)
MB12 (0)
MVR-C5252 (0)
MVR-T7011 (0)
NY-ESO-1 TCR-T cell therapy (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
OSE-279 (0)
PD-1-KO-T cell injection (0)
PF-07209960 (0)
PH-3861 (0)
PH-762 ACT (0)
PRGN-3007 (0)
(0)
RB-340 (0)
SAR445877 (0)
SL-279252 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TQB2868 (0)
TY 101 (0)
Undisclosed PD-1 inhibitor (0)
Undisclosed anti PD-1 mAb (0)
WTX212 (0)
XKDCT086 (0)
ZG005 (0)
YBL-006 (0)
anti-PD-1 antibody (0)
SI-B003 (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
SCT-I10A (0)
XmAb23104 (0)
AMG 256 (0)
LZM009 (0)
RG7769 (0)
MGD019 (0)
BMS-986298 (0)
MK-3475 SC (0)
CT-011 (0)
LVGN3616 (0)
MK-1308A (0)
IBI318 (0)
F520 (0)
AZD7789 (0)
RG6139 (0)
JS001sc (0)
MK-7684A (0)
AMG 404 (0)
trastuzumab (407)
afatinib (227)
lapatinib (107)
neratinib (102)
pyrotinib (79)
tucatinib (39)
trastuzumab-pkrb (24)
margetuximab-cmkb (18)
poziotinib (17)
zenocutuzumab-zbco (16)
KN026 (14)
mobocertinib (12)
trastuzumab-dttb (11)
zanidatamab-hrii (10)
trastuzumab-strf (9)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
LZM-005 (8)
PRS-343 (8)
D3L-001 (7)
inetetamab (6)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
MT-5111 (4)
TAS2940 (4)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
MET306 (4)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
DZD9008 (3)
trastuzumab-IFN-β mutein (3)
AST-301 (2)
Bay846 (2)
CT-0508 (2)
DF1001 (2)
ER121 (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
VIR-5818 (2)
BDC-1001 (2)
ABL105 (1)
ACE1702 (1)
Hercease (trastuzumab biosimilar) (1)
BAY 2927088 (1)
BAY2701439 (1)
DZD1516 (1)
GCC2003 (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
EG12014 (trastuzumab biosimilar) (1)
IAH0968 (1)
IMM2902 (1)
MP0274 (1)
RG6596 (1)
SAR443216 (1)
(1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
S-222611 (1)
KD019 (1)
ABT-101 (0)
ADG138 (0)
ALT02 (trastuzumab biosimilar) (0)
trastuzumab biosimilar (AP062) (0)
B-Vaxx (0)
BAT1006 (0)
BAY2701438 (0)
BMS690514 (0)
CAM-H2 (0)
CAT-179 (0)
CUDC-101 (0)
DA 3111 (trastuzumab biosimilar) (0)
(0)
ELVN-002 (0)
ES2B-C001 (0)
ETBX-021 (0)
(0)
GB235 (0)
HER-2/neu peptide vaccine (0)
HER2 t-haNK (0)
HF158K1 (0)
HLX11 (pertuzumab biosimilar) (0)
Hervycta (trastuzumab biosimilar) (0)
ISB 1302 (0)
JNJ-26483327 (0)
OST-HER2 (0)
MBS301 (0)
MM 111 (0)
MP412 (0)
MVA-BN-HER2 (0)
NVL-330 (0)
NeuCeptin (trastuzumab biosimilar) (0)
nelipepimut-S (0)
lapuleucel-T (0)
OS47701 (0)
QP34563457 (0)
ertumaxomab (0)
trastuzumab biosimilar (SIBP-01) (0)
SPH5030 (0)
(0)
Sym013 (0)
TAC100-HER2 (0)
TAK-285 (0)
TAS0728 (0)
TPIV100 (0)
TQB2930 (0)
glycooptimized trastuzumab-GEX (0)
TrastuRel (trastuzumab biosimilar) (0)
Undisclosed HER2Bi-armed ATC (0)
VM 206 (0)
YH42946 (0)
AST1306 (0)
cipatinib (0)
dHER2+AS15 (0)
KBP-5209 (0)
RG6194 (0)
AZD8931 (0)
trastuzumab biosimilar (0)
trastuzumab biosimilar (0)
pembrolizumab (727)
nivolumab (607)
sintilimab (115)
toripalimab-tpzi (88)
camrelizumab (85)
tislelizumab-jsgr (84)
dostarlimab-gxly (43)
cemiplimab-rwlc (29)
PDR001 (22)
zimberelimab (20)
ABBV-181 (13)
pucotenlimab (12)
cadonilimab (10)
AGEN2034 (9)
penpulimab (7)
serplulimab (7)
retifanlimab-dlwr (6)
PF-06801591 (6)
JNJ-63723283 (5)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
geptanolimab (3)
iparomlimab/tuvonralimab (3)
ivonescimab (3)
MEDI0680 (2)
QL1604 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
AZD2936 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
(0)
AI-061 (0)
AMP-224 (0)
ASKG915 (0)
AUNP-12 (0)
AWT020 (0)
(0)
BAT1306 (0)
BAT1308 (0)
BGB-108 (0)
BZD1901 (0)
BiCKI IL-7 (0)
CB213 (0)
CD200AR-L (0)
CDX-585 (0)
CMAB 819 (nivolumab biosimilar) (0)
EBV-specific anti-PD1 TCR-T cells (0)
EMB-02 (0)
enlonstobart (0)
prolgolimab (0)
GNR-051 (0)
HX-009 (0)
IAP0971 (0)
INCA32459 (0)
INCA33890 (0)
JS201 (0)
KJ-101 (0)
LB1410 (0)
MASCT-I (0)
MB12 (0)
MVR-C5252 (0)
MVR-T7011 (0)
NY-ESO-1 TCR-T cell therapy (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
OSE-279 (0)
PD-1-KO-T cell injection (0)
PF-07209960 (0)
PH-3861 (0)
PH-762 ACT (0)
PRGN-3007 (0)
(0)
RB-340 (0)
SAR445877 (0)
SL-279252 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TQB2868 (0)
TY 101 (0)
Undisclosed PD-1 inhibitor (0)
Undisclosed anti PD-1 mAb (0)
WTX212 (0)
XKDCT086 (0)
ZG005 (0)
YBL-006 (0)
anti-PD-1 antibody (0)
SI-B003 (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
SCT-I10A (0)
XmAb23104 (0)
AMG 256 (0)
LZM009 (0)
RG7769 (0)
MGD019 (0)
BMS-986298 (0)
MK-3475 SC (0)
CT-011 (0)
LVGN3616 (0)
MK-1308A (0)
IBI318 (0)
F520 (0)
AZD7789 (0)
RG6139 (0)
JS001sc (0)
MK-7684A (0)
AMG 404 (0)
trastuzumab (407)
afatinib (227)
lapatinib (107)
neratinib (102)
pyrotinib (79)
tucatinib (39)
trastuzumab-pkrb (24)
margetuximab-cmkb (18)
poziotinib (17)
zenocutuzumab-zbco (16)
KN026 (14)
mobocertinib (12)
trastuzumab-dttb (11)
zanidatamab-hrii (10)
trastuzumab-strf (9)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
LZM-005 (8)
PRS-343 (8)
D3L-001 (7)
inetetamab (6)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
MT-5111 (4)
TAS2940 (4)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
MET306 (4)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
DZD9008 (3)
trastuzumab-IFN-β mutein (3)
AST-301 (2)
Bay846 (2)
CT-0508 (2)
DF1001 (2)
ER121 (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
VIR-5818 (2)
BDC-1001 (2)
ABL105 (1)
ACE1702 (1)
Hercease (trastuzumab biosimilar) (1)
BAY 2927088 (1)
BAY2701439 (1)
DZD1516 (1)
GCC2003 (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
EG12014 (trastuzumab biosimilar) (1)
IAH0968 (1)
IMM2902 (1)
MP0274 (1)
RG6596 (1)
SAR443216 (1)
(1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
S-222611 (1)
KD019 (1)
ABT-101 (0)
ADG138 (0)
ALT02 (trastuzumab biosimilar) (0)
trastuzumab biosimilar (AP062) (0)
B-Vaxx (0)
BAT1006 (0)
BAY2701438 (0)
BMS690514 (0)
CAM-H2 (0)
CAT-179 (0)
CUDC-101 (0)
DA 3111 (trastuzumab biosimilar) (0)
(0)
ELVN-002 (0)
ES2B-C001 (0)
ETBX-021 (0)
(0)
GB235 (0)
HER-2/neu peptide vaccine (0)
HER2 t-haNK (0)
HF158K1 (0)
HLX11 (pertuzumab biosimilar) (0)
Hervycta (trastuzumab biosimilar) (0)
ISB 1302 (0)
JNJ-26483327 (0)
OST-HER2 (0)
MBS301 (0)
MM 111 (0)
MP412 (0)
MVA-BN-HER2 (0)
NVL-330 (0)
NeuCeptin (trastuzumab biosimilar) (0)
nelipepimut-S (0)
lapuleucel-T (0)
OS47701 (0)
QP34563457 (0)
ertumaxomab (0)
trastuzumab biosimilar (SIBP-01) (0)
SPH5030 (0)
(0)
Sym013 (0)
TAC100-HER2 (0)
TAK-285 (0)
TAS0728 (0)
TPIV100 (0)
TQB2930 (0)
glycooptimized trastuzumab-GEX (0)
TrastuRel (trastuzumab biosimilar) (0)
Undisclosed HER2Bi-armed ATC (0)
VM 206 (0)
YH42946 (0)
AST1306 (0)
cipatinib (0)
dHER2+AS15 (0)
KBP-5209 (0)
RG6194 (0)
AZD8931 (0)
trastuzumab biosimilar (0)
trastuzumab biosimilar (0)
›
Associations
News
Trials
Filter by
Latest
8ms
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=180, Recruiting, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
8 months ago
New P1 trial • Metastases
|
SSGJ-705
3years
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors (clinicaltrials.gov)
P1, N=162, Not yet recruiting, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
3 years ago
Clinical • New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
SSGJ-705
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login